Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹401.54 Cr |
| Fresh Issue | ₹165.00 Cr |
| Offer for Sale | ₹236.54 Cr |
| Face Value | ₹5 Per Equity Share |
| Price Band | ₹448.00-460.00 per share |
| Discount | Retail: 0.00 |
| BSE Code | 543329 |
| NSE Code | WINDLAS |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | SBI Capital Markets Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 30 shares and in multiples thereof
Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Competitive strengths
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Purchase of equipment required for (i) capacity expansion of the existing facility at the Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant – II | 50.00 |
| 2 | Funding incremental working capital requirements of the Company | 47.56 |
| 3 | Repayment/prepayment of certain of the borrowings | 20.00 |
| 4 | General corporate purposes( | 34.60 |
| Period Ended | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|
| Assets | 296.12 | 338.49 | 298.18 |
| Total Income | 430.70 | 331.34 | 311.53 |
| Profit After Tax | 15.57 | 16.21 | 63.82 |
| EBITDA | 54.52 | 34.00 | 37.74 |
| NET Worth | 199.12 | 209.66 | 193.59 |
| Reserves and Surplus | 192.71 | 203.25 | 187.17 |
| Total Borrowing | 31.32 | 27.43 | 29.91 |
| Amount in ₹ Crore | |||
